Lyon's Previa Medical announced it had raised €2.1 million in seed funds for its certified early diagnostics device for sepsis, powered by artificial intelligence software.
Dubbed SEPSI-SCORE, Previa's AI platform is based on the open exchange of electronic medical records. It is deployed to meet two main objectives: to reduce the sepsis mortality rate while also limiting the length of hospital stays as the patient recovers.
Previa Medical said the seed funds would support a new multicentre clinical trial to further validate its technology which allows clinicians to recognise and define sepsis infections, in some cases 48 hours before the disease becomes symptomatic. The AI is trained to understand personal data from the patient's electronic health records, for example the status of their vital signs.
Proceeds from the seed round will go to a recruitment drive to expand the reach of Previa's product, while preparing for its "full commercial launch phase." The device was certified as a medical device in 2021.
French investment bank Bpifrance featured in the round alongside fellow investors BNP Paribas, CCI Capital Croissance, Hopla Memory, Veymont Participations, M2care, and Holding Seraip.
Banque populaire AURA also backed the round, providing a mix of equity capital and loans.
Previa Medical resulted from an AI for health challenge launched in 2022 by Bpifrance and the French health ministry, which has awarded grant funding.
Sepsis refers to the body's most drastic biological response to an infection. While any bacterial infection left unchecked can cause sepsis, it is a grave emergency with risk to life as the body's immune system damages critical organs and tissues.
Would you like to write the first comment?Login to post comments